Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms

Figures & data

Table 1 Patient characteristics for diagnosis

Patient’s characteristics
Presence of megakaryocyte proliferation and atypia, accompanied by collagen fibrosis grade 3
Not meeting World Health Organization criteria for ET, PV, BCR/ABL positive CML, myelodysplastic syndromes, or other myeloid neoplasms
Presence of JAK2 mutation
Palpable splenomegaly, confirmed during two consecutive examinations LDH increased to above upper normal limit of institutional reference range, confirmed during two consecutive determinations
Dysplasia and hypocytosis
Abnormal chromosome karyotype, no MDS defining chromosomal abnormality
5%~20% blasts in bone marrow cytology, no preceding history of MPN or MDS, no recent cytotoxic or growth factor therapy

Abbreviations: ET, essential thrombocytosis; PV, polycythemia vera; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MPN, myelo proliferative neoplasms.